Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) The Rezdiffra prescribing information does not include a liver biopsy requirement ...

GLP-1RAs and SGL2 inhibitors were associated with lower risks for NAFLD and NASH among patients with type 2 diabetes. Newer classes of glucose-lowering agents may reduce risk for liver disease among ...

Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...

Because omega-3 polyunsaturated fatty acids have been shown to reduce hepatic dysfunction in NASH, but the molecular underpinnings of this action were elusive, researchers conducted a multiomic ...

Taking daily aspirin may prevent progression of nonalcoholic fatty liver disease (NAFLD) to liver fibrosis and nonalcoholic steatopepatitis (NASH), according to a study published online May 8 in ...

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug ...

Fatty liver disease happens when fat builds up in your liver. This can cause damage, inflammation, and other complications. There are two main types of fatty liver disease: Nonalcoholic fatty liver ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...